SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0000929638-22-000949
Filing Date
2022-05-23
Accepted
2022-05-23 17:00:46
Documents
3
Group Members
JEFF EASTONLIND GLOBAL MACRO FUND, LPLIND GLOBAL PARTNERS II LLCLIND GLOBAL PARTNERS LLC

Document Format Files

Seq Description Document Type Size
1 sched13g.htm SC 13G 95695
2 JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS exhibit99-1.htm EX-99.1 12747
3 ITEM 8 STATEMENT exhibit99-2.htm EX-99.2 1088
  Complete submission text file 0000929638-22-000949.txt   111246
Mailing Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103
Business Address TWO LOGAN SQUARE 100 N. 18TH STREET, SUITE 300 PHILADELPHIA PA 19103 (267) 207-3606
Vallon Pharmaceuticals, Inc. (Subject) CIK: 0001824293 (see all company filings)

IRS No.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-92206 | Film No.: 22952578
SIC: 2834 Pharmaceutical Preparations

Mailing Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022 646-701-7428
Lind Global Fund II LP (Filed by) CIK: 0001871665 (see all company filings)

IRS No.: 863914253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G